Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Trautmann-Grill, K. [1 ]
Lonial, S. [2 ]
Nooka, A. K. [2 ]
Thulasi, P. [3 ]
Badros, A. Z. [4 ]
Jeng, B. H. [4 ]
Callander, N. S. [5 ]
Sborov, D. [6 ]
Zaugg, B. E. [7 ]
Popat, R. [8 ]
Degli, Esposti S. [9 ,10 ]
Baron, J. [11 ]
Doherty, A. [12 ]
Lewis, E. [13 ]
Opalinska, J. [11 ]
Paka, P. [11 ]
Piontek, T. [11 ]
Gupta, I [11 ]
Farooq, A., V [14 ]
Jakubowiak, A. [14 ]
机构：
[1] Univ Klinkum Carl Gustav, Dresden, Germany
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA
[4] Univ Maryland, Sch Med, Baltimore, MD USA
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA
[8] Univ Coll London Hosp, NHS Fdn Trust, London, England
[9] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[10] UCL Inst Ophthalmol, London, England
[11] GlaxoSmithKline, Providence, RI USA
[12] GlaxoSmithKline, Collegeville, MN USA
[13] GlaxoSmithKline, Res Triangle Pk, NC USA
[14] Univ Chicago, Med Ctr, Chicago, IL USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep271
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [31] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Sagar Lonial
    Ajay K. Nooka
    Praneetha Thulasi
    Ashraf Z. Badros
    Bennie H. Jeng
    Natalie S. Callander
    Heather A. Potter
    Douglas Sborov
    Brian E. Zaugg
    Rakesh Popat
    Simona Degli Esposti
    Julie Byrne
    Joanna Opalinska
    January Baron
    Trisha Piontek
    Ira Gupta
    Reza Dana
    Asim V. Farooq
    Kathryn Colby
    Andrzej Jakubowiak
    Blood Cancer Journal, 11
  • [32] Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3
    Ferron-Brady, Geraldine
    Taylor, Adekemi
    Kaullen, Josh
    Polireddy, Kishore
    McKeown, Astrid
    Sule, Neal
    Struemper, Herbert
    BLOOD, 2023, 142
  • [33] LONGITUDINAL PHARMACODYNAMIC (PD) MODELS TO INVESTIGATE EFFICACY AND OCULAR SAFETY FOLLOWING BELANTAMAB MAFODOTIN (BELAMAF) ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Collins, J.
    van Noort, M.
    Rathi, C.
    Post, T.
    Struemper, H.
    Jewell, R.
    Ferron-Brady, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S16 - S17
  • [34] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
    Hungria, Vania T. M.
    Weisel, Katja
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Kouri, Fotini
    Liboon, John
    Brawley, Chris
    Lewis, Eric
    Tubel, Gabriela
    Li, Mary
    McKeown, Astrid
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [35] DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Biswas, Swethajit
    Holkova, Beata
    Jackson, Nicola
    Netherway, Thelma
    Paul, Sofia
    Ferron-Brady, Geraldine
    Yeakey, Anne
    Shelton, Chris
    de Oca, Rocio Montes
    Ahlers, Christoph Matthias
    Ballas, Marc S.
    Paul, Elaine Marie
    Gupta, Ira
    Opalinska, Joanna
    Luptakova, Katarina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
    Callander, Natalie S.
    Richardson, Paul G.
    Hus, Marek
    Ribrag, Vincent
    Lopez, Joaquin Martinez
    Kim, Kihyun
    Lee, Jae Hoon
    Dimopoulos, Meletis
    Schjesvold, Fredrik
    Facon, Thierry
    Jo, Jae-Cheol
    Min, Chang-Ki
    Mielnik, Michal
    Cheng, Shinta
    Smith, L. Mary
    Breitbach, Caroline J.
    Brawley, Chris
    Sembhi, Harjeet
    LaMacchia, John
    Hakim, Shawn
    Kremer, Brandon E.
    Grosicki, Sebastian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S507 - S508
  • [37] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
    Cohen, Adam D.
    Trudel, Suzanne
    Lonial, Sagar
    Libby, Edward N.
    Lee, Hans Chulhee
    Besemer, Britta
    Facon, Thierry
    Nooka, Ajay K.
    Callander, Natalie Scott
    Chari, Ajai
    Gupta, Ira
    Paul, Sofia
    Opalinska, Joanna
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
  • [39] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul G.
    Trudel, Suzanne
    Callander, Natalie S.
    Nooka, Ajay
    Song, Kevin
    Uttervall, Katarina
    Minnema, Monique C.
    Rodriguez-Otero, Paula
    Struemper, Herbert
    Yeakey, Anne
    de Oca, Rocio Montes
    Smith, L. Mary
    Jackson, Nicola
    Kaisermann, Morrys
    Im, Ellie
    Basile, Frank G.
    Ahlers, Christoph M.
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Quach, Hang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
  • [40] Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
    Lonial, Sagar
    Lee, Hans C.
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie
    Lendvai, Nikoletta
    Sborov, Douglas
    Suvannasankha, Attaya
    Weisel, Katja
    Karlin, Lionel
    Libby, Edward
    Arnulf, Bertrand
    Facon, Thierry
    Hulin, Cyrille
    Kortum, K. Martin
    Rodriguez-Otero, Paula
    Usmani, Saad Z.
    Hari, Parameswaran
    Baz, Rachid
    Hang Quach
    Moreau, Philippe
    Voorhees, Peter M.
    Gupta, Ira
    Hoos, Axel
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Jewell, Roxanne C.
    Dettman, Elisha J.
    Popat, Rakesh
    Esposti, Simona Degli
    Opalinska, Joanna
    Richardson, Paul
    Cohen, Adam D.
    LANCET ONCOLOGY, 2020, 21 (02): : 207 - 221
12345